CD19 and leukemia: NALM6 tumors treated with CD19.4–1BB CAR-T cells were still able to continue growing, suggesting that CD19.4–1BB CAR-T cells are either slower to home to tumor and/or slower to induce cytotoxicity against NALM6 leukemia.